

# Interim Report Vigmed Holding AB January - June 2014

For further information  
contact:

Chairman of the board  
Lennart Holm  
+46 70-630 856 or

CEO  
Finn Ketler  
+46 42 600 5311

During the first six months production of CLiP<sup>®</sup> Ven Ported started, the products were launched on the market, and Vigmeds first commercial sale occurred in June.

Distribution agreements have been signed for markets in Scandinavia, Greece, Italy, Spain and Portugal and quality management systems were established in both design and manufacture of medical technology products.

- Net Sales for the first six months was SEK 236 thousand (compared to SEK 0 during 2013)
- Operating profit in the first six months for the Group amounted to MSEK -13.5 (MSEK -11.3)
- Net income per share in the first half year was SEK -0.36 (SEK -0.32).

After the reporting period, on August 19, the Board of Vigmed Holding AB decided to form an operational company in China, and through this initiate registration of selected products on the Chinese market. Furthermore, a decision was made to initiate a process to prepare the company for a change of venue for the company's shares from NASDAQ OMX First North to NASDAQ OMX Stockholm Small Cap. This as a natural step in the anticipated growth of the company.

*Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: [www.vigmed.com/investor](http://www.vigmed.com/investor)*